Swiss National Bank
AMLX icon

Swiss National Bank’s Amylyx Pharmaceuticals AMLX Stock Holding History

Swiss National Bank’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.59M Buy
144,200
+13,900
+11% +$215K ﹤0.01% 1793
2026
Q1 		$1.81M Sell
130,300
-31,400
-19% -$442K ﹤0.01% 1907
2025
Q4 		$1.95M Buy
+161,700
New +$2.2M ﹤0.01% 1883
2024
Q2 		– Sell
-86,600
Closed -$246K – 2464
2024
Q1 		$246K Buy
86,600
+6,900
+9% +$90.2K ﹤0.01% 2502
2023
Q4 		$1.17M Buy
79,700
+13,200
+20% +$202K ﹤0.01% 2146
2023
Q3 		$1.22M Buy
66,500
+1,100
+2% +$23.3K ﹤0.01% 2129
2023
Q2 		$1.41M Buy
+65,400
New +$1.77M ﹤0.01% 2115

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Swiss National Bank's AMLX Position: Q2 2026 in Review

Swiss National Bank increased its Amylyx Pharmaceuticals (AMLX) stake by 11% in Q2 2026, buying an estimated $215K and bringing the position to 144,200 shares worth $2.59M. The position accounts for ﹤0.01% of the portfolio, ranked #1793.

Swiss National Bank first reported a position in AMLX in Q2 2023 and has held it in 7 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Swiss National Bank held 144,200 shares of Amylyx Pharmaceuticals worth $2.59M as of Q2 2026.
  • Swiss National Bank bought 13,900 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $215K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #1793 holding.
  • Swiss National Bank first reported a position in Amylyx Pharmaceuticals in Q2 2023 and has held it in 7 quarters since.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.